Patients with hereditary angioedema (HAE) present with recurrent, circumscribed, and self-limiting episodes of tissue or mucous membrane swelling caused by C1-inhibitor (C1-INH) deficiency. The estimated frequency of HAE is 1:50,000 persons. Distinguishing HAE from acquired angioedema (AAE) facilitates therapeutic interventions and family planning or testing. Patients with HAE benefit from treatment with attenuated androgen, antifibrinolytic agents, and C1-INH concentrate replacement during acute attacks. HAE is currently recognized as a genetic disorder with autosomal dominant transmission. Other forms of inherited angioedema that are not associated with genetic mutations have also been identified. Readily available tests are complement studies, including C4 and C1-esterase inhibitor, both antigenic and functional C1-INH. These are the most commonly used tests in the diagnosis of HAE. Analysis of C1q can help differentiate between HAE and AAE caused by C1-INH deficiency. Genetic tests would be particularly helpful in patients with no family history of angioedema, which occurs in about half of affected patients, and in patients whose C1q level is borderline and does not differentiate between HAE and AAE. Measuring autoantibodies against C1-INH also would be helpful, but the test is available in research laboratories only. Simple complement determinations are appropriate for screening and diagnosis of the disorder.
AAE = acquired angioedema; AAE-I = AAE type I; AAE-II = AAE type II; ACE = angiotensin-converting enzyme; C1-INH = C1 inhibitor; ε ε ε ε ε-ACA = ε ε ε ε ε-aminocaproic acid; FFP = fresh frozen plasma; HAE = hereditary angioedema; HAE-I = hereditary angioedema type I; HAE-II = hereditary angioedema type II; HF = Hageman factor; HFa = Hageman factor activated; HF f1+2 = Hageman factor subunits; HMWK = high-molecularweight kininogen; LMWK = low-molecular-weight kininogen; PCR = polymerase chain reaction; TA = tranexamic acid
DISEASE SYNOPSIS
The 2 major types of angioedema are acquired and hereditary. Acquired angioedema (AAE) is most commonly idiopathic, or it may be allergic in nature, related to medication effects, or characterized as an autoimmune disease or occurring in association with a lymphoproliferative disorder. 1 
Hereditary angioedema (HAE) is the result of mutations affecting the C1 inhibitor (C1-INH) gene (SERPING1) resulting in either loss of the C1-INH protein (HAE type I [HAE-I]) or loss of its function (HAE type II [HAE-II])
. [2] [3] [4] An estrogen-dependent form of angioedema is also believed to be hereditary, but it does not have a clear genetic mutation. 5, 6 Patients with HAE present with recurrent, circumscribed, and self-limiting episodes of tissue or mucous membrane swelling. The more common forms of angioedema, with or without urticaria, are allergic or idiopathic.
This article focuses mainly on HAE secondary to C1-INH deficiency, the genetics of HAE, and the mechanisms of and therapy for angioedema. It is currently recognized as a genetic disorder with autosomal dominant transmission that results from deficiency of C1-INH. 7 C1 inhibitor is a member of the serpin superfamily of serine protease inhibitors. C1 inhibitor is mainly produced in the parenchymal cells of the liver; other sites of production include monocytes, fibroblasts, endothelial cells, and microglial cells. It plays a pivotal role in the control of 4 different enzymatic cascadesthe complement system cascade, the coagulation cascade, the fibrinolytic cascade, and the kinin system ( Figure 1 ).
Other forms of HAE that are not associated with genetic mutations have also been identified. 5, 6, [8] [9] [10] [11] C1 inhibitor deficiency can be either genetic or acquired.
12-15 Angioedema due to C1-INH deficiency should be differentiated from the more common allergic 16 and idiopathic angioedema [17] [18] [19] as well as angioedema related to angiotensin-converting enzyme (ACE) inhibitors. [20] [21] [22] [23] [24] [25] [26] The estimated frequency of HAE is 1:50,000 persons. 4, 8, 15, 27 Despite the identification of multiple mutations in the C1-INH gene (SERPING1), the precise mechanism of angioedema resulting from these mutations remains elusive. The field of HAE investigation progressed slowly during the past few decades, in part because of the small number of patients with this disorder. However, because of the identification of a pivotal role for C1-INH in other diseases or complications, 28 ,29 such as endotoxemia, 30 coronary artery disease, 31 capillary leak syndromes, 32 and transplant rejection, [33] [34] [35] developments in the field may occur much more quickly than in the past.
CLINICAL PRESENTATION
Patients with HAE usually present with a history of recurrent angioedema affecting the face, lips, tongue, genitalia, extremities, or larynx. 36 Some give a history of angioedema GENETIC TESTS FOR HEREDITARY ANGIOEDEMA and present with ascites or bouts of abdominal pain from bowel angioedema. 37, 38 Fifty percent of patients with HAE have laryngeal edema in addition to recurrent angioedema and abdominal pain. 39, 40 Rarely, patients with HAE have cerebral edema, 41,42 pleural effusions, or symptoms suggestive of bladder involvement. 43 Some patients have an erythematous rash called erythema marginata associated with attacks of angioedema. This rash may resemble urticaria, and in fact, it can be confused with urticaria, although typical urticaria is not part of HAE. Laryngeal angioedema has the potential of being fatal. Because the therapy for angioedema depends on precise diagnosis, diagnostic criteria for HAE were established by the Third C1 Esterase Inhibitor Deficiency Workshop 8 (Table 1 ). In our judgment, the main requirements for the diagnosis of HAE (other than history and physical examination) are abnormal results on complement studies, and some patients have abnormal complement results with minimal or no symptoms for years before they become symptomatic.
Several clinical forms of HAE have been described. According to the most recent nomenclature, 8 the different types are given the designations HAE-I, HAE-II, 44 and estrogen-dependent or estrogen-associated inherited angioedema (formerly HAE-III). A recent report of a family with angioedema affecting 3 brothers (normal level and function of C1-INH) might represent yet an additional category. 45 Also, AAE is subtyped as AAE types I and II (AAE-I and AAE-II) 8 (Table 2) . By far the most common form is idiopathic angioedema, which is not associated with any complement abnormalities or other allergy and is commonly associated with urticaria. The cause remains indeterminate. Cicardi et al 18 have called this "nonhistaminergic angioedema." Many patients with idiopathic angioedema that is not associated with urticaria do not respond to antihistamines. Some of these patients respond to tranexamic acid (TA), an antifibrinolytic agent. 18 Although this article mainly discusses HAE, readers should know that angioedema, with or without urticaria, is common, and often no cause is found.
Identification of the type of angioedema facilitates both therapeutic interventions and family testing or planning. For example, patients with HAE benefit from treatment with attenuated androgen, antifibrinolytic agents, and C1-INH concentrate replacement. Acquired angioedema I might be associated with B-cell-type lymphoproliferative disorders 46-49 and AAE-II with autoimmune disorders.
50-54
Clear distinction between AAE-I and AAE-II is not always possible. 53,54 Drug-induced and allergic angioedema require the identification and withdrawal of the precipitating agent.
PATHOPHYSIOLOGY OF ANGIOEDEMA AND THE RATIONALE FOR THERAPY
The mechanism of angioedema in the absence of C1-INH appears to be secondary to increased levels of bradykinin. [55] [56] [57] [58] [59] [60] C1 inhibitor is a regulatory enzyme that plays a role in 4 different but interrelated pathways the contact system generates. 61 These include the complement cascade, the coagulation cascade, the kinin 62 pathway, and the fibrinolytic system [63] [64] [65] [66] [67] [68] [69] ( Figure 1 ). The Complement Cascade and the Generation of Bradykinin. During activation of the complement pathway (Figure 1 ), C1q, C1r, and C1s are activated by plasmin. The Hageman factor (HF) subunits HF f1+2 might be able to activate some C1. 65, [70] [71] [72] [73] [74] [75] Activated C1 induces hydrolysis and activation of C4 and C2 simultaneously. C4 forms C4a and C4b, and C2 forms C2a and C2b. C2b, in the presence of plasmin, either forms or degrades to C-kinin.
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The Role of Coagulation, Fibrinolysis, and Plasma Kallikrein Cascades in the Generation of Bradykinin. The coagulation, fibrinolysis, and plasma kallikrein cascades are interrelated. 77 Parts of those cascades are also controlled by C1-INH ( Figure 1 ). Hageman factor (coagulation factor XII) 78 is activated by plasma kallikrein 79 in the presence of high-molecular-weight kininogen (HMWK) 80, 81 to become active HF (HFa). In turn, HFa induces the activation of coagulation factor XI to become XIa. Coagulation factor XIa (also called activated plasma thromboplastin antecedent) is one of the early steps in the coagulation pathway.
Both factor XIa and HFa induce the formation of plasmin from plasminogen. 75, 82 Plasmin causes the activation of C1 and the formation of kinin and bradykinin from C2b. Active HF is subsequently induced by plasma kallikrein in the presence of HMWK to form 2 HF subunits, HF f1+2 (prekallikrein activator). HF f1+2 induce the formation of plasma kallikrein from prekallikrein (kallikinogen), 83 which is 80% complexed to HMWK. Plasma kallikrein 84 not only activates HF (XII) further but also induces the formation of bradykinin 75, 76 from kininogen (in the presence of HMWK). 76, 77, 85 Tissue kallikrein causes the formation of kallidin (lys-bradykinin) from low-molecularweight kininogen (LMWK), 76, 77, 86 but this step is not regulated by C1-INH. The end product is the generation of bradykinin. 65, 79, 87, 88 The Role of C1-INH as It Down-Regulates the Generation of Bradykinin. C1 inhibitor is a serpin that modulates the complement, coagulation, 89 kinin, 76 and fibrinolytic pathways. 63, 68, [90] [91] [92] C1 inhibitor inhibits the formation of activated C1 and the cleavage of C2 and C4. Also, C1-INH inhibits the ability of plasmin to activate C1 and to cause the generation of bradykinin 93 from C2. In the absence or reduced function of C1-INH, the formation of bradykinin is increased, and patients experience angioedema. Another factor that may increase bradykinin through this pathway is tissue-type plasminogen activator (increases level of plasmin), which has also been reported to cause angioedema. [94] [95] [96] [97] [98] [99] C1 inhibitor 100 85 ,107, 108 and C1 activation and therefore reduces the generation of bradykinin. The absence of C1-INH, or its function, results in an uncontrolled generation of bradykinin, which appears to be the major cause of angioedema. 58, 59, 68 The Role of Other Protease Inhibitors and Bradykinin Production. Other protease inhibitors can inhibit some of these pathways as well. 109 Antithrombin III 110,111 inhibits the formation of HF f1+2 and the effect of plasma kallikrein 107,111 on kininogen, HMWK, 112 and LMWK. 113 Antithrombin III also inhibits the ability of plasmin to induce the generation of bradykinin. Three other protease inhibitors-β 2 -macroglobulin, α 1 -antitrypsin, 114, 115 and α 2 -antiplasmin 116, 117 -inhibit both plasma kallikrein 113 and plasmin. These other antiproteases may have a therapeutic [118] [119] [120] in the absence of C1-INH even though they do not appear to be equipotent.
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Physiology of Other Bradykinin-Modulating Agents.
Other factors that affect the cascades previously mentioned include ε-aminocaproic acid (ε-ACA) 121, 122 and TA. 121, 123 Both ε-ACA and TA 124, 125 are antifibrinolytic agents 126 that inhibit plasmin; ε-ACA is not a potent inhibitor of activated C1 complement. 127, 128 Both agents are useful in the treatment of HAE. 121, 129 Of note, all reported mutations in C1-INH are heterozygous. 8, 130 Whether this indicates that the complete absence (homozygous trait) of C1-INH is lethal is unknown. The role of attenuated androgens as therapeutic agents becomes apparent, given their ability to increase the level of C1-INH. 131 In vitro studies have shown the ability of interferon-γ to stimulate production of C1-INH; however, in vivo, this has not resulted in therapeutic benefit.
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Degradation and Elimination of Bradykinin and Angioedema. Bradykinin is inactivated by carboxypeptidase N, 133, 134 aminopeptidase P, 135 neutral endopeptidase, 8 bradykinin receptor binding, 8 and ACE. 8, 61, 65, 136, 137 The role of ACE for the degradation of bradykinin is critical. 138 Only 1 report has been published of a patient with familial ACE deficiency who presented with recurrent angioedema. 139 Patients taking ACE inhibitors have the propensity to develop angioedema, probably because of an accumulation of bradykinin. 137, 140 A subgroup of these patients developed angioedema with angiotensin receptor blockers. 141 The effect of ACE inhibitors is important not only for patients with HAE and AAE but also for patients who are deficient in other factors that metabolize bradykinin, such as carboxypeptidase N 65, 133 or aminopeptidase P. 135 One patient with carboxypeptidase N deficiency has been reported to develop angioedema, 133 probably because of the accumulation of bradykinin.
A question remains about why HAE symptoms are intermittent and the clinical expression of this genetic abnormality is so variable, with some patients having severe symptoms and others having minimal, infrequent, or even no symptoms. Patient observation suggests that stress or minor trauma might precipitate angioedema. Almost all patients with HAE have a low C4 and a low antigenic or functional C1-INH, even though their attacks are intermittent. Rarely, patients exhibit the laboratory abnormalities only during an episode of angioedema.
THERAPEUTIC INTERVENTIONS
There are 3 approaches to therapy for patients with HAE. The first is immediate therapy during an attack, the second is short-term prophylaxis before dental or surgical procedures, and the third is long-term prophylaxis. Although therapy for HAE and AAE overlaps somewhat, there are clear distinctions, especially in HAE's acute (life-threatening) stage. The urgent and long-term prophylactic therapy for different forms of angioedema depends on the type. A therapeutic algorithm for HAE is outlined in Figure 2 and Table 3 .
Emergency Therapy for Acute Angioedema. The main goal of immediate therapy in an emergency situation (such as laryngeal edema) is to maintain an open airway. 40, 142 This might require intubation or a tracheostomy and ventilator support. Intubation may not be possible if laryngeal edema is advanced. Therefore, intubation should be considered early in the patient presentation if airway compromise is impending. Abdominal pain from gut edema may require pain control. Therefore, it is important to identify the type of angioedema because patients with HAE respond to C1-INH concentrate.
143-147 All other therapies do not abort the attack but might reduce its duration. Most reports are from uncontrolled studies, and some are anecdotal; they describe use of high doses of attenuated androgens, 49,148-155 fibrinolytic agents 121, 123 (TA, 124, 125, [156] [157] [158] [159] and ε-ACA 127-129,160
), or fresh frozen plasma (FFP). 161 Of these modalities, only C1-INH concentrate has proven benefit. The use of FFP in the acute angioedema of HAE remains controversial because it also gives more substrate and may worsen angioedema. The most common cause of angioedema, often does not respond to antihistamines; has been called "nonhistaminergic" by Cicardi et al. 18 Mechanism remains unknown *AAE = acquired angioedema; C1-INH = C1 inhibitor; HAE = hereditary angioedema.
Treatment with epinephrine for reversal of airway compromise may help patients with allergic angioedema but is of controversial benefit for patients with HAE. 162, 163 Patients with AAE may also benefit from the addition of systemic antihistamines and corticosteroids. 163 Corticosteroids are of little benefit for patients with HAE.
8,164
Short-term and Long-term Prophylaxis Therapeutic Options. Identification and Withdrawal of Precipitating Agent. Patients with HAE or AAE with a known precipitating factor, such as ACE inhibitors 21, [165] [166] [167] [168] [169] [170] [171] or angiotensin receptor blockers, 26, 171 should discontinue the medication. Patients with estrogen-dependent angioedema and those with HAE made worse by estrogens should discontinue oral contraceptives or hormone therapy. 5, 8 Withdrawal of estrogen therapy helps patients with estrogen-dependent angioedema and might help patients with HAE. Stress may precipitate acute attacks of angioedema.
Fresh Frozen Plasma. Fresh frozen plasma has been used for treatment of acute exacerbations and HAE prophylaxis. 161, 172, 173 Patients with severe recalcitrant ACE-induced angioedema have benefited from the administration of FFP. 24 The concern in HAE, however, is that FFP might provide the factors that make the angioedema worse. The use of FFP remains controversial and lacks controlled studies. We have not used it in patients with acute attacks.
C1-INH Concentrate. For patients with an acute exacerbation of HAE-I or HAE-II, replacement of the missing enzyme is the ideal therapy.
174 C1 inhibitor concentrate is the preferred therapy for patients with HAE who present with acute laryngeal edema 40, [145] [146] [147] 175 that might otherwise be fatal. C1 inhibitor replacement with the concentrate is of benefit for some but not all patients with AAE-II, 52 possibly due to inadequate dosing.
Long-term prophylaxis with C1-INH is necessary when treatment with other agents is not effective or not tolerated. A pasteurized concentrate of C1-INH administered for 1 year to 1 patient with HAE and for 1 year to another patient with AAE rendered both patients symptom-free without reported adverse effects.
176 C1 inhibitor concentrate is ideal therapy for patients with infrequent attacks, those not fre- quent enough to warrant long-term prophylaxis. However, the concentrate is not yet available on the US market. Attenuated Androgens. Attenuated androgens are the mainstay of prophylactic therapy for both HAE and AAE. Attenuated androgens are used for short-and long-term prophylaxis.
Multiple androgens such as testosterone, 177 methyltestosterone, 178 fluoxymesterone, and oxymetholone were early therapeutic agents for HAE. They markedly decreased the frequency of attacks of edema without serious adverse effects. Subsequently, more attenuated 17α-alkylated corticosteroids (danazol and stanozolol) also were found to have therapeutic benefit. 149, 150, 152 Short-term prophylaxis before planned surgery or dental procedures 155 requires a transient increase in the therapeutic dose ( Figure 3 ). For short-term prophylaxis, danazol, up to 600 mg/d, is given for 5 days before surgery. Increased doses of other androgenic agents can also be used.
The dosage at which danazol is used for long-term prophylactic treatment ranges from 50 to 600 mg/d ( Figure  4 ). Stanozolol is used at 2 to 12 mg/d, and methyltestosterone at 10 to 30 mg/d. A typical treatment regimen is to start adult patients at the highest dose divided into 3-times-daily doses for the initial 4 weeks, then tapering the dosage every 4 weeks to the minimal effective dose. Another treatment approach starts at lower doses and increases the dose if needed ( Figure 4 and Table 3 ). If the patient has frequent or severe episodes of angioedema, we start with the high dose and taper; however, if the patient has mild or infrequent episodes of angioedema, we choose the lower dose and increase as needed. The minimal effective dose should be used for maintenance therapy. Some patients do well with every-other-day dosing. Danazol doses as low as 200 mg every 2 or 3 days and stanozolol at 2 mg/d (or even every second or third day) have been used successfully to reduce attack frequency. They are effective in preventing attacks at these low doses even though the results of complement studies remain abnormal.
Long-term prophylactic measures are outlined in Figure  4 . Long-term use of danazol and stanozolol can cause irregular menstruation, hepatotoxicity, 153, 154 masculinization in women and children (acne, increased hair growth, weight gain, deepening of the voice), behavioral changes (aggression or depression), weight gain, and hypertension. Other adverse effects include alteration of blood lipid levels and coagulation factors 179 and polycythemia. 155 The potential for inducing hepatocellular neoplasms and liver vascular lesions (peliosis hepatica) should alert the physician to check levels of α-fetoprotein and to perform liver ultrasonography annually. 180 Other possible risks include prostate adenocarcinoma; therefore, an annual digital rectal examination and a prostate-specific antigen determination are important. 8, 149, 153, 154, 179 Attenuated androgens are relatively contraindicated in children.
Stanozolol is no longer manufactured for use in humans in the United States, although it is still available for veterinary use. Some compounding pharmacies can make it available for human use.
Antifibrinolytic Agents. Antifibrinolytic agents (plasmin inhibitors), such as TA and ε-ACA, are also used for prophylaxis against attacks.
ε-Aminocaproic Acid. ε-Aminocaproic acid is used clinically as an antifibrinolytic agent. 122, 181, 182 In 1968, ε-ACA was successfully given to a patient after an attack of angioedema. Since then other studies have demonstrated its potential beneficial role in this condition.
127,129 It has been used for acute therapy 183 as well as short-term 128 and longterm prophylaxis. 160 ε-Aminocaproic acid, 16 g/d, adequately controls HAE; however, lower doses (7-10 g) taken daily in divided doses might be sufficient. 160 The major adverse effect of ε-ACA is myalgia, with or without rhabdomyolysis. 184, 185 Thrombosis is another potential complication.
186 Muscle weakness, hypotension, and fatigue may also occur with the use of higher doses. 160 Tranexamic Acid. Tranexamic acid is a synthetic antifibrinolytic amino acid that binds plasminogen and blocks its function. It is commonly used for the prevention of excessive bleeding. 121, 182, [187] [188] [189] [190] [191] Treatment of HAE patients with TA reduces the frequency of swelling in 70% of the patients. 156, 157 Because of the virilizing effects of androgens, TA can be used as the first agent of choice in children with HAE. Also, TA is of use in AAE 18, 192 and is safe for use in pregnancy (class B).
On a mole per mole base, TA is 7 times more potent than ε-ACA. Its plasma half-life is about 80 minutes, and it is cleared through the kidney. The usual total dosage of TA is 25 to 75 mg/kg of body weight given in divided doses 2 to 3 times daily. Once the patient is symptom-free, the dose should be tapered to the minimum effective level. The dose could be tapered by 30% every 2 months until the reappearance of symptoms. 18 Therapy reduces the frequency and intensity of symptoms without greatly changing any biochemical parameters. 
GENETIC TESTS FOR HEREDITARY ANGIOEDEMA
Tranexamic acid can be used with acute episodes 183 and for short-term and long-term prophylaxis. 158 The main adverse effects of TA are nausea, diarrhea, and sensation of laryngeal or pharyngeal dryness. 18 Arterial thrombosis is one of the potential risks of TA therapy. 18, 193 POTENTIAL THERAPEUTIC AGENTS Potential therapeutic agents other than C1-INH replacement include agents that would replace the C1-INH function, interfere with major steps in the pathway of bradykinin generation, or block the effector function of bradykinin. Another potential therapeutic modality is gene therapy. The following agents have been studied. Plasma Kallikrein Antagonists. Plasma kallikrein is one of the important mediators in the pathophysiology of angioedema. A plasma kallikrein antagonist DX-88 120, 194, 195 is currently under investigation for therapeutic use in patients with HAE and appears promising.
Bradykinin Antagonists. Bradykinin is a nanopeptide that appears to be at the center of the pathogenesis of angioedema in patients with HAE 57, 58, 60, 88 as well as in mouse models of C1-INH deficiency. 59 The disputed C2 complement kinin likely has similar function. 55, [65] [66] [67] 88, 196 Bradykinin, however, is involved in the mediation of several other processes. Those processes include inflammation, 61, 76, 197 cardioprotection, 198 bronchoconstriction, [199] [200] [201] [202] blood pressure control, 203,204 neuroprotection, 205 and nociceptive (pain) nerve transmission. 206, 207 Therefore, it is logical to consider use of bradykinin antagonists to ameliorate the angioedema in HAE. [207] [208] [209] [210] [211] The B2 bradykinin receptor in a mouse model appears to have a major role in angioedema. To date, 1 bradykinin antagonist, icatibant, has been tested and granted therapeutic orphan drug status showing benefit in both the mouse model and human angioedema.
Serine Protease Inhibitors. Several protease inhibitors share some of the functions of C1-INH. 109 These include antithrombin III, 107,110,111,113 114, 115 and α 2 -antiplasmin. 116, 117 These protease inhibitors and others have a potential use as therapeutic agents [118] [119] [120] 212 despite their lower potency. 120 
GENETIC BACKGROUND OF HAE C1-INH DEFICIENCY: HAE-I AND HAE-II
Hereditary angioedema is an autosomal dominant disorder associated with mutations in the C1-INH gene. This gene, SERPING1, is located in the q12-q13.1 subregion of chromosome 11. The C1-IHN gene comprises 8 exons. 213 Many kinds of mutations have been described; they can occur in the exons or in the regions controlling gene expression. If the mutation results in the loss of production of C1-INH protein, HAE-I develops. If the mutation results in the generation of a nonfunctional mutant protein, HAE-II develops. Anomalies related to this gene result in HAE-I and HAE-II. Other genetic variants of HAE that occur in the presence of completely normal C1-INH level and function have been described. 214 Only about 50% of patients have a positive family history, suggesting the occurrence of spontaneous mutations.
C1 inhibitor deficiency has 2 major phenotypes: HAE-I and HAE-II. Both have C1-INH function at 5% to 30% of normal instead of the 50% expected if the single normal allele were fully expressed ( Table 2) . Hereditary angioedema type I (about 85% of C1-INH-associated HAE) is associated with almost absent expression (level and function) of C1-INH. [215] [216] [217] In HAE-II (about 15% of C1-INHassociated HAE), C1-INH is expressed but is not functional (normal or high level but reduced function). 213, [218] [219] [220] Each disorder can result from one of many mutations in the SERPING1. [221] [222] [223] These include point mutations, 224, 225 deletions, 226 substitution, 227 duplication, 228 frame shift, 229 premature stop codon, 230 and many others. 8, 15, 130, [231] [232] [233] [234] [235] Not all SERPING1 mutations result in clinical disease. 236 An online database of documented mutations is available at hae.biomembrane.hu.
ESTROGEN-DEPENDENT HAE
This type of HAE was recently described and affects women only in conditions with elevated levels of serum estrogen. 5, 9 Patients present with symptoms identical to patients with HAE-I and HAE-II, but symptoms occur in the setting of normal C1-INH level and function as well as genetic makeup. 6, 214 The inheritance appears to be mendelian autosomal dominant, and these patients appear to have increased sensitivity to estrogen. To date, the genetic anomaly has yet to be identified. 8 This type should be differentiated from HAE-I or HAE-II because the C1-INH deficiency is exacerbated with hormonal changes. 10, 237, 238 
RATIONALE FOR TESTS IN HAE
Hereditary angioedema presents in a fashion similar to all other types of angioedema. About half the patients do not have a family history of the disorder. The diagnosis of the type of angioedema is important not only for identification of therapeutic options but also for family planning and counseling. If the family history is positive, the diagnosis is easier to make.
DIAGNOSIS
To date, genetic testing for HAE is available only in the research laboratory because of the multitude of different mutations leading to the disorder. Thus, complement stud-ies are the important diagnostic studies and the only ones readily available. The correct diagnosis is essential for appropriate therapy, management during childhood, management of the acute attack, and during pregnancy.
After a clinical presentation suggestive of a diagnosis of HAE, studies to determine whether the patients fulfill the diagnostic criteria (Table 1 ) must be performed. Readily available tests are complement studies including C4 and both antigenic and functional C1-INH. These are the most commonly used in the diagnosis. C1q can help differentiate between HAE and AAE. A diagnostic algorithm is presented in Figure 5 , and the differential diagnosis is summarized in Table 4 .
Laboratory findings in the different types of angioedema are compared in Table 4 . Genetic tests would be particularly helpful in patients with no family history of angioedema, which occurs in about half the patients with HAE, and the C1q is borderline and does not differentiate between HAE and AAE. Measuring autoantibodies against C1-INH also would be helpful, but this test currently is done only in research laboratories.
FAMILY COUNSELING
Given the autosomal dominant inheritance of the disorder, family counseling is important. Patients and their families need to be educated about the disease and its inheritance. This may result in appropriate therapeutic interventions for affected family members. Close follow-up of the patients and their families is essential, with appropriate tests performed at regular intervals. Prenatal screening is not yet feasible.
METHODS OVERVIEW OF SPECIFIC GENETIC TESTS USED IN HAE
Fluorescence-Assisted Mismatch Analysis. Appropriate gene regions of the wild-type and the putative mutant allele are simultaneously amplified from genomic DNA by GENETIC TESTS FOR HEREDITARY ANGIOEDEMA polymerase chain reaction (PCR) analysis, and large DNA fragments (up to 800 base pairs) are end-labeled with strand-specific fluorophores. 242 Cleavages occurring on opposite strands are detected by denaturing gel electrophoresis using an automated DNA sequencer. The sensitivity of detection is also increased. Automatic superimposition of tracings from different subjects allows mismatch detection even when the mutant chromosome is diluted 10-fold or more compared with the normal chromosome.
Specific PCR Amplification and Real-Time PCR Analysis. Real-time PCR analysis following Southern blot analysis can be used with direct sequencing to study SERPING1, the C1-INH gene. Large deletions can be detected by this technique. 234 Real-time quantitative reverse transcription-PCR analysis has also been used successfully to measure C1-INH messenger RNA levels in peripheral blood mononuclear cells. 243 Also, PCR analysis can be used to measure the level of expression of C1-INH messenger RNA in peripheral blood mononuclear cells. Levels of mRNA can be quantitated by computerized optical densitometry of reverse transcriptase-PCR products. 131 Fluorescent multiplex assay can be constructed to amplify simultaneously 5 exons of C1-INH. Polymerase chain reaction protocols using forward and reverse primers can be optimized for amplicons (size range between 300 and 700 base pairs). Superposing fluorescent profiles of test and control DNA can be done. This technique is suitable for screening the C1-INH gene in patients with HAE before screening for point mutations.
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Chemical Cleavage of Mismatches Technology. Selective reactions of mismatched thymine and cytosine base pairs with osmium tetroxide and hydroxylamine, respectively, can be used to separate and identify the resulting fragments after digestion by gel electrophoresis. 244 This method has been used to detect pathogenic SERPING1 mutations 245 and analyze its polymorphism. The efficiency of this technique depends on the mismatch and the stability of the adjacent sequences. Fluorescent probes have been used to develop fluorescence-assisted mismatch analysis.
242,244-247
Denaturing High-Performance Liquid Chromatography and Gradient Gel Electrophoresis. This technique uses polyacrylamide gels with linearly increasing concentrations of a denaturing agent for studying the migration of double-stranded DNA. 248, 249 The genomic DNA segments are amplified, identified, and directly sequenced.
Single-Stranded Conformational Analysis. In nondenaturing gel electrophoresis, the mobility of heat-denatured single strands depends on secondary structure formation. 250, 251 This technique is simple, inexpensive, and highly sensitive.
TEST INDICATIONS AND INTERPRETATION OF RESULTS IN PATIENTS WITH HAE
Laboratory testing is indicated for all patients with recurrent episodes of angioedema of undetermined etiology. Testing is especially important after the demonstration of C4 complement consumption with an abnormal C1-INH level or function. Interpretation of those tests and their relation to different disorders are outlined in Table 4 .
When an individual receives the diagnosis of HAE, other family members need to be tested. Children are asymptomatic at birth, but close clinical and laboratory follow-up is indicated for appropriate management when needed. Early testing will also help the family members make informed decisions about future family planning. 239 ‡A normal C4 concentration was reported in 1 patient. 240 §At least 1 patient with normal C1q level was reported. ⁄⁄Female patients and 1 male patient wth recurrent angioedema caused by androgen deficiency. 241 Some patients also had urticaria. 
